Skip to content
2000
image of Promising Response to Pyrotinib in Non-Small-Cell Lung Cancer with the Rare HER2 R456C Mutation: A Case Report

Abstract

Background

exon 20 insertions exhibit relative resistance to chemotherapy and covalent HER2-targeted tyrosine kinase inhibitors (TKIs) in non-small-cell lung cancer (NSCLC). Furthermore, specific missense mutations in the extracellular domain of the HER2 protein have been identified as oncogenic drivers in NSCLC. However, their structural properties and clinical response to HER2-targeted inhibitors remain poorly understood, warranting further investigation. R456C represents a rare exon 12 missense mutation in the HER2 extracellular domain, with limited documentation in NSCLC.

Case Presentation

This study presents an atypical case of NSCLC with a R456C mutation, where the patient experienced a favorable response and substantial survival benefit from the HER2-targeted inhibitor pyrotinib. A patient, a 65-year-old man diagnosed with stage IIIB lung adenocarcinoma, initially underwent radical concurrent chemoradiotherapy. Upon disease recurrence, polymerase chain reaction assay detected no oncogenic alterations, and programmed cell death ligand 1 (PD-L1) expression was negative. Chemotherapy in combination with bevacizumab resulted in stable disease, providing a progression-free survival (PFS) benefit of 6 months. However, anlotinib proved ineffective against brain metastasis, necessitating brain radiotherapy. A subsequent lung biopsy confirmed adenocarcinoma and next-generation sequencing identified a somatic exon 12 missense mutation, p.R456C. Following pyrotinib administration, the patient’s pulmonary metastases significantly diminished, and the brain metastasis regressed, resulting in a partial response and a PFS benefit of 13 months.

Conclusion

To the best of our knowledge, this study represents the first reported case demonstrating the promising efficacy of pyrotinib in -altered NSCLC harboring the rare exon 12 R456C mutation. Heterogeneous alterations in the HER2 extracellular segment, such as R456C, may be targetable and could confer survival benefits with HER2-targeted inhibitors.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccdt/10.2174/0115680096371951250409093625
2025-05-12
2025-09-13

  • From This Site

    /content/journals/ccdt/10.2174/0115680096371951250409093625
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Arcila M.E. Chaft J.E. Nafa K. Roy-Chowdhuri S. Lau C. Zaidinski M. Paik P.K. Zakowski M.F. Kris M.G. Ladanyi M. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. Clin. Cancer Res. 2012 18 18 4910 4918 10.1158/1078‑0432.CCR‑12‑0912 22761469
    [Google Scholar]
  2. Mazières J. Peters S. Lepage B. Cortot A.B. Barlesi F. Beau-Faller M. Besse B. Blons H. Mansuet-Lupo A. Urban T. Moro-Sibilot D. Dansin E. Chouaid C. Wislez M. Diebold J. Felip E. Rouquette I. Milia J.D. Gautschi O. Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives. J. Clin. Oncol. 2013 31 16 1997 2003 10.1200/JCO.2012.45.6095 23610105
    [Google Scholar]
  3. Shigematsu H. Takahashi T. Nomura M. Majmudar K. Suzuki M. Lee H. Wistuba I.I. Fong K.M. Toyooka S. Shimizu N. Fujisawa T. Minna J.D. Gazdar A.F. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 2005 65 5 1642 1646 10.1158/0008‑5472.CAN‑04‑4235 15753357
    [Google Scholar]
  4. Dziadziuszko R. Smit E.F. Dafni U. Wolf J. Wasąg B. Biernat W. Finn S.P. Kammler R. Tsourti Z. Rabaglio M. Ruepp B. Roschitzki-Voser H. Stahel R.A. Felip E. Peters S. Afatinib in NSCLC with HER2 mutations: Results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP). J. Thorac. Oncol. 2019 14 6 1086 1094 10.1016/j.jtho.2019.02.017 30825613
    [Google Scholar]
  5. Kris M.G. Camidge D.R. Giaccone G. Hida T. Li B.T. O’Connell J. Taylor I. Zhang H. Arcila M.E. Goldberg Z. Jänne P.A. Targeting HER2 aberrations as actionable drivers in lung cancers: Phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann. Oncol. 2015 26 7 1421 1427 10.1093/annonc/mdv186 25899785
    [Google Scholar]
  6. Greulich H. Kaplan B. Mertins P. Chen T.H. Tanaka K.E. Yun C.H. Zhang X. Lee S.H. Cho J. Ambrogio L. Liao R. Imielinski M. Banerji S. Berger A.H. Lawrence M.S. Zhang J. Pho N.H. Walker S.R. Winckler W. Getz G. Frank D. Hahn W.C. Eck M.J. Mani D.R. Jaffe J.D. Carr S.A. Wong K.K. Meyerson M. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl. Acad. Sci. USA 2012 109 36 14476 14481 10.1073/pnas.1203201109 22908275
    [Google Scholar]
  7. Petrelli F. Tomasello G. Barni S. Lonati V. Passalacqua R. Ghidini M. Clinical and pathological characterization of HER2 mutations in human breast cancer: A systematic review of the literature. Breast Cancer Res. Treat. 2017 166 2 339 349 10.1007/s10549‑017‑4419‑x 28762010
    [Google Scholar]
  8. Jasra S. Opyrchal M. Norton L. Mehta R. A rare case of S310F somatic ERBB2 mutation in a HER2-nonamplified breast cancer. Clin. Breast Cancer 2017 17 1 e37 e41 10.1016/j.clbc.2016.08.001 27665021
    [Google Scholar]
  9. Vornicova O. Hershkovitz D. Yablonski-Peretz T. Ben-Itzhak O. Keidar Z. Bar-Sela G. Treatment of metastatic extramammary Paget’s disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F. Oncologist 2014 19 9 1006 1007 10.1634/theoncologist.2014‑0054 25085898
    [Google Scholar]
  10. Wang J. Wen Y. Ding G. Ding P. Zhang L. Liu J. Zhang T. Yang L. Efficacy generated by afatinib in a lung adenocarcinoma patient harboring HER2 S310Y mutation. Cancer Biol. Ther. 2018 19 6 450 453 10.1080/15384047.2018.1449611 29561699
    [Google Scholar]
  11. Ou S.H.I. Schrock A.B. Bocharov E.V. Klempner S.J. Haddad C.K. Steinecker G. Johnson M. Gitlitz B.J. Chung J. Campregher P.V. Ross J.S. Stephens P.J. Miller V.A. Suh J.H. Ali S.M. Velcheti V. HER2 transmembrane domain (TMD) mutations (V659/G660) that stabilize homo- and heterodimerization are rare oncogenic drivers in lung adenocarcinoma that respond to afatinib. J. Thorac. Oncol. 2017 12 3 446 457 10.1016/j.jtho.2016.11.2224 27903463
    [Google Scholar]
  12. Jia Z. Xing J. Li J. Wang W. Wang Y. Song Y. Yang X. Xue J. Ye J. Li B. Han-Zhang H. Zhao J. Zhang X. Peng F. Chen F. Chen X. Lu Y. Ying S. Wu D. Zhang X. Ma C. Lai L. Ma S. Liang D. Liu P. Li X. Liang N. Li S. HER2 transmembrane domain mutation: Comprehensive characteristics and real-world evidence of treatment response in Chinese lung adenocarcinoma. Transl. Lung Cancer Res. 2021 10 3 1383 1396 10.21037/tlcr‑21‑107 33889517
    [Google Scholar]
  13. Yang G. Liu R. Li P. Yang Y. Wang Y. Mao H. Tang X. Clinical and structural insights into the rare but oncogenic HER2-activating missense mutations in non-small cell lung cancer: A retrospective ATLAS cohort study. Discover Oncology 2024 15 1 285 10.1007/s12672‑024‑01154‑2 39012378
    [Google Scholar]
  14. Goto K. Goto Y. Kubo T. Ninomiya K. Kim S.W. Planchard D. Ahn M.J. Smit E.F. de Langen A.J. Pérol M. Pons-Tostivint E. Novello S. Hayashi H. Shimizu J. Kim D.W. Kuo C.H. Yang J.C.H. Pereira K. Cheng F.C. Taguchi A. Cheng Y. Feng W. Tsuchihashi Z. Jänne P.A. Trastuzumab deruxtecan in patients with HER2 -Mutant metastatic non–small-cell lung cancer: Primary results from the randomized, phase II DESTINY-Lung02 trial. J. Clin. Oncol. 2023 41 31 4852 4863 10.1200/JCO.23.01361 37694347
    [Google Scholar]
  15. Gupta G. Hussain M.S. Pant K. Ali H. Thapa R. Bhat A.A. Antibody-drug conjugates (ADCs): A novel therapy for triple-negative breast cancer (TNBC). Curr. Cancer Drug Targets 2025 25 2 108 112 10.2174/0115680096343056240828190900 39248064
    [Google Scholar]
  16. Boscolo Bielo L. Trapani D. Nicolò E. Valenza C. Guidi L. Belli C. Kotteas E. Marra A. Prat A. Fusco N. Criscitiello C. Burstein H.J. Curigliano G. The evolving landscape of metastatic HER2-positive, hormone receptor-Positive breast cancer. Cancer Treat. Rev. 2024 128 102761 10.1016/j.ctrv.2024.102761 38772169
    [Google Scholar]
  17. Zhou J. Ding N. Xu X. Zhang Y. Ye M. Li C. Hu J. Clinical outcomes of patients with HER2 -mutant advanced lung cancer: Chemotherapies versus HER2 -directed therapies. Ther. Adv. Med. Oncol. 2020 12 1758835920936090 10.1177/1758835920936090 32647540
    [Google Scholar]
  18. Auliac J.B. Dô P. Bayle S. Doubre H. Vinas F. Letreut J. Falchero L. Hauss P.A. Thomas P. Chouaid C. Non-small cell lung cancer patients harboring HER2 mutations: Clinical characteristics and management in a real-life setting. Cohort HER2 EXPLORE GFPC 02-14. Adv. Ther. 2019 36 8 2161 2166 10.1007/s12325‑019‑01001‑9 31154630
    [Google Scholar]
  19. Hyman D.M. Piha-Paul S.A. Won H. Rodon J. Saura C. Shapiro G.I. Juric D. Quinn D.I. Moreno V. Doger B. Mayer I.A. Boni V. Calvo E. Loi S. Lockhart A.C. Erinjeri J.P. Scaltriti M. Ulaner G.A. Patel J. Tang J. Beer H. Selcuklu S.D. Hanrahan A.J. Bouvier N. Melcer M. Murali R. Schram A.M. Smyth L.M. Jhaveri K. Li B.T. Drilon A. Harding J.J. Iyer G. Taylor B.S. Berger M.F. Cutler R.E. Jr Xu F. Butturini A. Eli L.D. Mann G. Farrell C. Lalani A.S. Bryce R.P. Arteaga C.L. Meric-Bernstam F. Baselga J. Solit D.B. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 2018 554 7691 189 194 10.1038/nature25475 29420467
    [Google Scholar]
  20. Zhou C. Li X. Wang Q. Gao G. Zhang Y. Chen J. Shu Y. Hu Y. Fan Y. Fang J. Chen G. Zhao J. He J. Wu F. Zou J. Zhu X. Lin X. Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: A multicenter, open-label, single-arm, phase II study. J. Clin. Oncol. 2020 38 24 2753 2761 10.1200/JCO.20.00297 32614698
    [Google Scholar]
  21. Yang G. Hao X. Hu J. Dong K. Xu H. Yang L. Zhang S. Yang Y. Xu F. Li J. Wang Y. Pyrotinib in HER2 heterogeneously mutated or amplified advanced non-small cell lung cancer patients: A retrospective real-world study (PEARL). JNCC 2021 1 4 139 146 10.1016/j.jncc.2021.08.001 39036804
    [Google Scholar]
  22. Yang G. Xu H. Yang Y. Zhang S. Xu F. Hao X. Li J. Xing P. Hu X. Liu Y. Wang L. Lin L. Wang Z. Duan J. Wang J. Wang Y. Pyrotinib combined with apatinib for targeting metastatic non-small cell lung cancer with HER2 alterations: A prospective, open-label, single-arm phase 2 study (PATHER2). BMC Med. 2022 20 1 277 10.1186/s12916‑022‑02470‑6 36031613
    [Google Scholar]
  23. Yang Y. Yang G. Li W. Hao X. Zhang S. Ai X. Lei S. Xu H. Wang Y. Pyrotinib plus antiangiogenic agents for HER2 ‐altered advanced non‐small cell lung cancer: A retrospective real‐world study. Thorac. Cancer 2023 14 33 3275 3281 10.1111/1759‑7714.15118 37740599
    [Google Scholar]
  24. Giannakis M. Mu X.J. Shukla S.A. Qian Z.R. Cohen O. Nishihara R. Bahl S. Cao Y. Amin-Mansour A. Yamauchi M. Sukawa Y. Stewart C. Rosenberg M. Mima K. Inamura K. Nosho K. Nowak J.A. Lawrence M.S. Giovannucci E.L. Chan A.T. Ng K. Meyerhardt J.A. Van Allen E.M. Getz G. Gabriel S.B. Lander E.S. Wu C.J. Fuchs C.S. Ogino S. Garraway L.A. Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma. Cell Rep. 2016 15 4 857 865 10.1016/j.celrep.2016.03.075 27149842
    [Google Scholar]
  25. Yang G. Yang Y. Liu R. Li W. Xu H. Hao X. Li J. Xing P. Zhang S. Ai X. Xu F. Wang Y. First-line immunotherapy or angiogenesis inhibitor plus chemotherapy for HER2 -altered NSCLC: A retrospective real-world POLISH study. Ther. Adv. Med. Oncol. 2022 14 17588359221082339 10.1177/17588359221082339 35251321
    [Google Scholar]
  26. Yang G. Liu R. Tang X. Dacomitinib exhibits promising activity against the rare HER2 exon 20 insertion M774delinsWLV in lung cancer: A case report and literature review. Heliyon 2024 10 9 e30312 10.1016/j.heliyon.2024.e30312 38707278
    [Google Scholar]
  27. Jumper J. Evans R. Pritzel A. Green T. Figurnov M. Ronneberger O. Tunyasuvunakool K. Bates R. Žídek A. Potapenko A. Bridgland A. Meyer C. Kohl S.A.A. Ballard A.J. Cowie A. Romera-Paredes B. Nikolov S. Jain R. Adler J. Back T. Petersen S. Reiman D. Clancy E. Zielinski M. Steinegger M. Pacholska M. Berghammer T. Bodenstein S. Silver D. Vinyals O. Senior A.W. Kavukcuoglu K. Kohli P. Hassabis D. Highly accurate protein structure prediction with AlphaFold. Nature 2021 596 7873 583 589 10.1038/s41586‑021‑03819‑2 34265844
    [Google Scholar]
  28. Yang Z. Zeng X. Zhao Y. Chen R. AlphaFold2 and its applications in the fields of biology and medicine. Signal Transduct. Target. Ther. 2023 8 1 115 10.1038/s41392‑023‑01381‑z 36918529
    [Google Scholar]
/content/journals/ccdt/10.2174/0115680096371951250409093625
Loading
Promising Response to Pyrotinib in Non-Small-Cell Lung Cancer with the Rare HER2 R456C Mutation: A Case Report
Bentham Science Publishers ; https://doi.org/10.2174/0115680096371951250409093625
/content/journals/ccdt/10.2174/0115680096371951250409093625
/content/journals/ccdt/10.2174/0115680096371951250409093625
Loading

Data & Media loading...


  • Article Type:     Review Article
Keywords: non-small-cell lung cancer ; extracellular domain ; HER2 ; R456C mutation ; pyrotinib

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test